Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19Derek C. Angus, Balasubramanian Venkatesh, Mark Fitzgerald et al.|JAMA|2020Cited by 884
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 TrialA. Jo Chien, Laura J. Esserman, Debasish Tripathy et al.|Journal of Clinical Oncology|2020Cited by 113
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S. Clark, Laura J. Esserman, Christina Yau et al.|Nature Communications|2021Cited by 73